Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A Review of 1000 Molecular Investigations of Rare Inherited Anaemia and Related Conditions with the Red Cell Gene Panel

Rachel Mayhew, Frances Smith, Laura Steedman, Nicholas Parkin, Eva Moldes Beiro, Peter Rushton, Alison Bybee, David Brawand, Judith Marsh, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Shreyans Ghandi, Sahar Mansour, Ghulam Mufti, Antonio Pagliuca, Subarna Chakravorty, David C Rees, Barnaby Clark

Blood (2018) 132 (Supplement 1): 3609.

https://doi.org/10.1182/blood-2018-99-118799

Published: 2018

Journal Articles

Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry

Álvaro Urbano-Ispizua, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Marije Bartels, MD PhD, Christopher J. Patriquin, MD MSc, FRCPC, Britta Hoechsmann, MD, Alexey A. Maschan, MD, Amanda Wilson, PhD, Philippe Gustovic, MD, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2018-99-111306

Published: 2018

Journal Articles

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Regis Peffault De Latour, Jaroslaw P. Maciejewski, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Loree Larratt, MD FRCP(C), Ronald S. Go, MD, David Dingli, MD PhD, Amanda Wilson, PhD, Philippe Gustovic, MD, Aleksandr Kulagin

Blood (2018) 132 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2018-99-111324

Published: 2018

Journal Articles

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

André Tichelli, MD, Regis Peffault De Latour, Jakob R. Passweg, MD PhD, Cora Knol, Gérard Socié, MDPhD, Judith Marsh, Britta Hoechsmann, MD, Hubert Schrezenmeier, MD, Andrea Bacigalupo, MD, Sujith Samarasinghe, Alicia Rovo, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Dirk-Jan Eikema, Paul Bosman, Peter Bader, MD PhD, Antonio M. Risitano, MD PhD, Carlo Dufour, MD

Blood (2018) 132 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2018-99-111811

Published: 2018

Journal Articles

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Robert A. Brodsky, MD, Regis Peffault De Latour, Scott T. Rottinghaus, MD, Alexander Röth, MD, Antonio M. Risitano, MD PhD, Ilene C. Weitz, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jaroslaw P. Maciejewski, Jeffrey Szer, MBBS, Jong-Wook Lee, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Lori Volles, MD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Lori Shafner, PhD, Anita Hill, MD PhS, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2018-99-110874

Published: 2018

Journal Articles

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Anita Hill, MD PhS, Scott T. Rottinghaus, MD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong-Wook Lee, MD PhD, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeffrey Szer, MBBS, Antonio M. Risitano, MD PhD, Shinji Nakao, MD PhD, Eric Bachman, Lori Shafner, PhD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Alexander Röth, MD, Regis Peffault De Latour

Blood (2018) 132 (Supplement 1): 625.

https://doi.org/10.1182/blood-2018-99-119147

Published: 2018

Journal Articles

Prognostic and Predictive Impact of Small PNH Clones in a Large Cohort of Patients with Myelodysplastic Syndromes and Aplastic Anemia: A Single-Center Experience

Bruno Fattizzo, MD, Alan Dunlop, Robin M. Ireland, FRCP, Shireen Kassam, MD, Dario Consonni, MD, Deborah Yallop, MBBS FRCP FRCPath PhD, Ghulam J. Mufti, Judith Marsh, Alberto Zanella, MD, Wilma Barcellini, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3870.

https://doi.org/10.1182/blood-2018-99-116772

Published: 2018

Journal Articles

Neoantigens in MDS Are Associated with Two Novel CD4+ T Cell Subsets and Improved Overall Survival

Thomas Coats, MD, Alexander E Smith, PhD, Athanasios Mourikis, Tala Shahin, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Steve Best, PhD, Sneha Chitre, Richard Ellis, Nedyalko Petrov, Susanne Heck, Jonathan Michael Irish, PhD, Shahram Kordasti, MD PhD, Ghulam Mufti, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 2958.

https://doi.org/10.1182/blood.V130.Suppl_1.2958.2958

Published: 2017

Journal Articles

Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance

Varun Mehra, MRCP, FRCPath, Titilola Oyebamiji, Stefanie Widya, Robin M. Ireland, FRCP, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Kavita Raj, MD PhD, Donal McLornan, Judith Marsh, MD, Victoria Potter, Joanna Large, Isabel Duggins, Aytug Kizilors, PhD, Nicholas Lea, PhD, Antonio Pagliuca, MD, Ghulam Mufti, DM, FRCP, FRCPath, Hugues De Lavallade

Blood (2017) 130 (Supplement 1): 5250.

https://doi.org/10.1182/blood.V130.Suppl_1.5250.5250

Published: 2017

Journal Articles

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Anita Hill, MBChB (Hons), PhD, Wynne Weston-Davies, MB FRCS, Miles Nunn, PhD, Tadeusz Robak, MD PhD, Jerzy Windyga, MD, Andrzej Hellmann, MD PhD DSc, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Agniezka Piekarska, Anna Szmigielska-Kaplon, Morag Griffin, Talha Munir

Blood (2017) 130 (Supplement 1): 4747.

https://doi.org/10.1182/blood.V130.Suppl_1.4747.4747

Published: 2017

Journal Articles

Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization

ELISA Bono, MD, Donal McLornan, Erica Travaglino, Shreyans Gandhi, MBBS,MDMNAMS, Anna Gallì, Alesia Abigael Khan, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Emanuela Boveri, Kavita Raj, Chiara Elena, Robin M. Ireland, FRCP, Antonio Bianchessi, Jie Jiang, Gabriele Todisco, Luca Malcovati, MD, Judith Marsh, MD, Mario Cazzola, MD, Ghulam Mufti, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 588.

https://doi.org/10.1182/blood.V130.Suppl_1.588.588

Published: 2017

Journal Articles

P53 Protein Expression Correlates with Adverse Outcome in Low-Risk Myelodysplastic Syndromes

Francesca Donatelli, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Alexander e Smith, PhD, Jon Salisbury, Syed A Mian, BSc, M.Phil, Robin M. Ireland, FRCP, FRCPath, Abu Arqoub Hadil, Victoria T Potter, Ghulam J. Mufti, MD PhD

Blood (2016) 128 (22): 5505.

https://doi.org/10.1182/blood.V128.22.5505.5505

Published: 2016

Journal Articles

Targeted Sequencing of 647 Patients with Myeloid Malignancies, Marrow Failures and Cytopenia: A Prospective Analysis

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Steven Best, PhD, Aytug Kizilors, PhD, Shreyans Gandhi, MD DNB, MRCP, FRCPath, Victoria T Potter, Judith C. W. Marsh, MD FRCP, FRCPath, Nicholas Lea, PhD, Robin M. Ireland, FRCP, FRCPath, Ghulam J Mufti, MD

Blood (2016) 128 (22): 1981.

https://doi.org/10.1182/blood.V128.22.1981.1981

Published: 2016

Journal Articles

Telomere Length and Telomerase Assay Assist in Identifying Novel Telomere Gene Complex Mutations in a Cohort of Patients with Aplastic Anemia

Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath, Jie Jiang, PhD, Nana Benson-Quarm, B.Sc, Dip (Nursing), Hanna Renshaw, MBBS, MA, Syed A Mian, BSc, M.Phil, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Judith C. W. Marsh, MD FRCP, FRCPath

Blood (2015) 126 (23): 667.

https://doi.org/10.1182/blood.V126.23.667.667

Published: 2015

Journal Articles

Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease

Francesco Grimaldi, MD, Pilar Perez-Abellan, Steven Best, PhD, Nicholas Lea, PhD, John Veluchamy, Muhammad Atif, MD, Rosemary Grain, Monica Sen, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Victoria T Potter, MD FRCPA, FRACP, Ghulam J Mufti, FRCP, FRCPath, Judith C.W. Marsh, MD, Linda D Barber, PhD

Blood (2015) 126 (23): 3129.

https://doi.org/10.1182/blood.V126.23.3129.3129

Published: 2015

Journal Articles

Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy

Magnus Tobiasson, MD, Donal McLornan, MDPhD, Mohsen Karimi, Marios Dimitriou, PhD, Monika Jansson, Asmaa Ben Azenkoud, Martin Jädersten, Greger Lindberg, Hani Abdulkadir, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Johanna Ungerstedt, Associate Professor, Andreas Lennartsson, Karl Ekwall, Ghulam J Mufti, Eva Hellström-Lindberg, MD PhD

Blood (2015) 126 (23): 2839.

https://doi.org/10.1182/blood.V126.23.2839.2839

Published: 2015

Journal Articles

An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML

Blood (2015) 126 (23): 710.

https://doi.org/10.1182/blood.V126.23.710.710

Published: 2015

Journal Articles

NLRP3 Inflammosome Polymorphisms Are Enriched in Myelodysplastic Syndrome Patients with Autoimmune Disorders

Syed A Mian, BSc, M.Phil, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Aytug Kizilors, PhD, Kathy L McGraw, PhD, Shahram Kordasti, MD PhD, Stephan Menzel, PhD, Alexander e Smith, PhD, Pilar Perezabellan, BSc, David Sallman, MD, Alan F. List, MD, Ghulam J Mufti, FRCP, FRCPath

Blood (2015) 126 (23): 1659.

https://doi.org/10.1182/blood.V126.23.1659.1659

Published: 2015

Journal Articles

Mutations in Cohesin Complex As Potential Targets for Therapeutic Intervention By PARP (Poly ADP Ribose Polymerase) Inhibitors in Myelodysplastic Syndrome

Nazia Matto, Terry J Gaymes, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Syed A Mian, BSc, M.Phil, Ghulam J Mufti, FRCP, FRCPath

Blood (2015) 126 (23): 1221.

https://doi.org/10.1182/blood.V126.23.1221.1221

Published: 2015

Journal Articles

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Antonio M Risitano, MD PhD, Michael Storek, Leonardo Sahelijo, MD, Mittie Doyle, Yang Dai, Ilene Ceil Weitz, MD, Judith C.W. Marsh, MD, Modupe Elebute, MBChB, MD, Casey L O'Connell, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Giridharan Ramsingh, MD, Serena Marotta, MD, Andrzej Hellmann, Ante S. Lundberg, MD

Blood (2015) 126 (23): 2137.

https://doi.org/10.1182/blood.V126.23.2137.2137

Published: 2015

NARROW

A Review of 1000 Molecular Investigations of Rare Inherited Anaemia and Related Conditions with the Red Cell Gene Panel

Efficacy of Eculizumab in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria in the International PNH Registry

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Prognostic and Predictive Impact of Small PNH Clones in a Large Cohort of Patients with Myelodysplastic Syndromes and Aplastic Anemia: A Single-Center Experience

Neoantigens in MDS Are Associated with Two Novel CD4+ T Cell Subsets and Improved Overall Survival

Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization

P53 Protein Expression Correlates with Adverse Outcome in Low-Risk Myelodysplastic Syndromes

Targeted Sequencing of 647 Patients with Myeloid Malignancies, Marrow Failures and Cytopenia: A Prospective Analysis

Telomere Length and Telomerase Assay Assist in Identifying Novel Telomere Gene Complex Mutations in a Cohort of Patients with Aplastic Anemia

Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy

An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML

NLRP3 Inflammosome Polymorphisms Are Enriched in Myelodysplastic Syndrome Patients with Autoimmune Disorders

Mutations in Cohesin Complex As Potential Targets for Therapeutic Intervention By PARP (Poly ADP Ribose Polymerase) Inhibitors in Myelodysplastic Syndrome

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only